Seaport Therapeutics filed pricing terms for a $201 million initial public offering scheduled to close this week, becoming the first neuropsychiatric biotech to test U.S. public markets since November. The Boston-based company develops central nervous system therapies and holds no marketed products. Renaissance Capital flagged the pricing notice Tuesday morning.

Seaport's pipeline centers on STP-6073, a Phase 2 candidate targeting major depressive disorder, and STP-2101, a preclinical GABA modulator for epilepsy. The company last raised $225 million in Series B funding led by Deerfield Management in October 2023, pricing that round at an undisclosed pre-money valuation. Underwriters include J.P. Morgan, Leerink Partners, and TD Cowen. The offering represents roughly 18-22% dilution based on typical biotech IPO structures, though exact share count remains unconfirmed.

This marks the earliest calendar neuropsychiatric IPO since Neumora Therapeutics priced a $250 million offering in February 2024 and subsequently traded down 41% through year-end. Psychiatric drug developers face compressed multiples after Sage Therapeutics' $1.5 billion zuranolone launch underperformed consensus by 67% in its first four quarters, and Axsome Therapeutics trades at 4.2x forward sales despite approval momentum. Allocators pulled $890 million from biotech-focused mutual funds in December alone, per Morningstar flows. Seaport's willingness to price into this environment suggests either pricing discipline or investor fatigue with private rounds.

The neuropsych category itself remains fractured. While Karuna Therapeutics commanded a $14 billion Bristol Myers Squibb acquisition in December 2023, that deal capitalized on a late-stage schizophrenia asset with visible Phase 3 data. Seaport's STP-6073 completed a 180-patient Phase 2 trial in November, posting topline results the company called statistically significant but not yet peer-reviewed. The delta between Karuna's exit multiple and current public comps suggests investors now separate late-stage psychiatric stories from earlier bets. Seaport's timing places it in the latter.

Watch whether the deal prices at or below the midpoint of its undisclosed range, typically a 15-18% discount signal. If Seaport opens below issue price on day one, expect two follow-on neuropsych IPOs currently in SEC registration—names unconfirmed but rumored to include a Boston anxiety-disorder play—to delay into March at minimum. Conversely, a clean tape through Friday strengthens the case for $1.2-1.8 billion in biotech IPO volume before the end of Q1, matching 2024's anemic first-quarter pace.

The company's underwriters collected $47 million in fees across the last eight CNS IPOs, five of which now trade beneath issue. Seaport's test is whether $201 million in primary capital justifies public-market risk when private neuro-focused crossover funds still hold $3.1 billion in dry powder.